Analyse Co-Diagnostics, Inc. (CODX) — Kairos Score 55/100

À propos de Co-Diagnostics, Inc.

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Co-Diagnostics, Inc..

🏦 Hedge Funds

4 fonds institutionnels déclarent une position sur CODX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur CODX.

• Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
• Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.